Brain Imaging Biomarkers in Patients With Brain Metastasis
Recruiting now Phase 2 NCT04197297
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
Who can join (things the study team will check)
✅ You may be able to join if…
- Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
- At least one index lesion with diameter > 1cm and without imaging evidence of hemorrhage
- Patients age > 18 years of age
- Patients planned for RT to brain metastases
- Ability to understand and the willingness to sign a written informed consent document.
🚫 You may not be able to join if…
- Previous Whole Brain Radiotherapy
- Previous radiosurgery to the index lesion
- Individuals unable to undergo contrasted MRI for whatever reason
Where this trial is running
- University Health Network, Toronto, Ontario, Canada
Who to contact
David Shultz, M.D., Ph. D · 416-946-6899 · david.shultz@rmp.uhn.on.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04197297.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.